The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera
Abstract
BACKGROUND: Several studies have recently reported on the occurrence of a JAK2 V617F mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS: In a single institutional study, mutation screening for JAK2 V617F was performed in DNA derived from archived blood granulocytes from 63 consecutive patients with PV in whom current diagnostic criteria were strictly applied and the diagnosis confirmed by bone marrow histology. RESULTS: The JAK2 V617F mutant allele was detected in 58 of the 63 patients (92%) with 21% homozygosity. The clinical phenotype of the five patients with the wild‐type allele was otherwise typical for the disease. A statistical comparison between JAK2 V617F heterozygotes (n = 45 patients) and homozygotes (n = 13 patients) did not reveal any significant associations with regard to age, gender, leukocyte or platelet count at the time of diagnosis, duration of disease, or the incidences of thrombosis or bleeding. However, compared with their heterozygote counterparts, JAK2 V617F homozygote patients displayed a significantly higher hemoglobin level at the time of diagnosis (P = 0.001), an increased incidence of pruritus (69% vs. 38%; P = 0.04), a higher rate of fibrotic transformation (23% vs. 2%; P = 0.009), and higher PRV‐1 transcript levels in their blood granulocytes (P = 0.07). CONCLUSIONS: The results of the current clinical study support previous laboratory observations that link JAK2 V617F with the PV phenotype by demonstrating a mutant allele dose effect on erythrocytosis and clinical and laboratory features characteristic of PV. Cancer 2006. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843 · cited 5×
“Conversely, JAK2 homozygosity is relatively frequent in patients with PV (approximately 25–33%), although it seldom occurs in other MPD patients.(6,7) Such observations warrant a closer examination of the clinical phenotype that is associated with different JAK2 mutational profiles in patients with PV.”
BackgroundResultInfluential
Cited by
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationVannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Rampal, R., Al-Shahrour, F., Abdel-Wahab, O., Patel, J. P., Brunel, J.-P., Mermel, C. H., Bass, A. J., Pretz, J., Ahn, J., Hricik, T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554634 · Cited by 428
Self-citationMesa, R. A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A. D., Atherton, P. J., Sloan, J. A., & Tefferi, A. (2007) · Cancer · doi:10.1002/cncr.22365 · Cited by 399
Self-citationPassamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370
Metadata
- Authors
- Tefferi, A., Lasho, T. L., Schwager, S. M., Strand, J. S., Elliott, M., Mesa, R., Li, C., Wadleigh, M., Lee, S. J., & Gilliland, D. G.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-12-20
- Volume
- 106
- Issue
- 3
- Pages
- 631-635
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2093290834
- Cited by
- 221
- References
- 1
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.